Subcutaneous recombinant GM-CSF given in combination with ipilimumab improved the overall survival and reduced ipilimumab-related toxicity in patients with advanced melanoma.88 The adjuvant activity of GM-CSF is exploited in the FDA-approved drug talimogene laherparepvec (T-VEC). The gene discussed is CSF2; the disease is melanoma.